Weight and cholesterol dipped when a hormone returned to normal
Original title: Cardiometabolic effects of sequential prolactin states in dopamine agonist-treated prolactinoma patients: a retrospective longitudinal study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors only looked back at past patient records, so this is not proof.
The short version
When a hormone called prolactin came back to normal, people weighed a little less.
What was studied. Doctors looked back at records for 47 people with a prolactinoma. That is a growth in the pituitary gland that raises prolactin. All of them took a drug called cabergoline, at 19 hospitals in Spain.
What they found. As prolactin went from high to normal, average weight fell from 80.4 kg to 78.7 kg. Total cholesterol fell from 194.3 to 178.7 mg/dL, and body mass index dropped a little too. When prolactin later fell below normal, no further changes were seen.
What this means, and what it doesn't
What it could mean: For people taking cabergoline, bringing prolactin back to normal may come with small drops in weight and cholesterol. Pushing prolactin below normal did not seem to add more benefit.
What it doesn't mean: This does not mean the drug fixes weight or cholesterol problems. It is not a cure for a tumor. Doctors only looked back at old records from a small group of people. That kind of study cannot show what caused what. The authors say larger studies are still needed. Nothing here changes the care you get today.
Source: PubMed, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.